Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655898 · ClinicalTrials.gov registry record · Phase 1
Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04655898 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 8 participants.
The verdict
NCT04655898, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a clinical pharmacology study to characterize the biotransformation and excretion of \[14C\]CC-90001 and to evaluate the safety and tolerability of \[14C\]CC-90001 following a single oral dose of \[14C\]CC-90001 in healthy male subjects. Approximately 8 subjects will be enrolled into the study with a goal of 6 subjects being eligible for analysis.
Interventions
- DRUG [14C]CC-90001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-12-16 |
| Est. Completion | 2021-03-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04655898
The ClinicalTrials.gov registry entry for NCT04655898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]CC-90001 is the first listed.
NCT04655898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04655898 about?
NCT04655898 is a clinical study titled "Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects". This is a clinical pharmacology study to characterize the biotransformation and excretion of \[14C\]CC-90001 and to evaluate the safety and tolerability of \[14C\]CC-90001 following a single oral dose of \[14C\]CC-90001 in healthy male subjects. Approximately 8 subjects will be enrolled into the stu...
What is the current status of trial NCT04655898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-12-16. Estimated completion is 2021-03-11.
What interventions are being tested in trial NCT04655898?
The interventions under investigation include: [14C]CC-90001 (DRUG).
Who is sponsoring clinical trial NCT04655898?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.